surmount-1 tirzepatide weight loss percent nejm 2022 Updates in Medicine | Phase 3 SYNCHRONIZE-1: Survodutide delivered up to 13% at 76 weeks, with substantial reductions in visceral and liver fat Semaglutide vs. Tirzepatide for Obesity

Individuals who are pregnant, nursing, or managing certain thyroid conditions should consult a physician before pursuing GLP-1 therapy of any kind

AKI is a reversible condition if you address it promptly, but it can be serious if left untreated

Compounded Medication Safety Notice: The FDA has identified concerns involving compounded GLP-1 products, including dosing errors, improper storage during shipping, fraudulent products, adverse-event reports, and semaglutide salt forms

It passes into breast milk only in small quantities (less than 1% of the maternal dose), with no adverse effects reported in breastfed infants